Key facts
- It has raised $22.3M.
- Notable investors include Tech Incubator Program for Startup, iM Investment Partners, Magna Investment (Seoul), HB Investment, Hanwha Investment & Securities Company — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Enterobiome
- ·The full record, as it builds
Funding rounds
No funding rounds for Enterobiome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enterobiome
Developer of microbial-based bio pharma biotic products designed to treat and cure human diseases. The company's products are developed for immune diseases, metabolic disorders, aging-related diseases, and cancer, enabling patients to recover quickly and improve the quality of their lives.
- Sector
- Healthcare
- HQ
- Goyang, South Korea
- Founded
- 2018
- Employees
- 29
- Website
- enterobiome.com/
- Ownership
- Privately Held (backing)
Enterobiome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enterobiome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enterobiome in its N-PORT filings yet. We sweep new filings monthly.